Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
See our latest analysis for Madrigal Pharmaceuticals. Despite the recent 7 day share price return of 13.44% decline and a softer 30 day move, Madrigal's 90 day share price return of 19.66% alongside a 1 year total shareholder return of 51.68% suggests that longer term momentum remains stronger than the short term pullback implies. If this kind of volatility in a single name has your attention, it can be useful to broaden the view with other healthcare stocks that are catching interest right now. With Madrigal trading around US$514.06 and screens flagging a value score of 4 plus a large intrinsic discount of about 72%, the key question is whether this signals a buying opportunity or whether the market is already pricing in future growth. Against the last close of US$514.06, the most followed narrative sees fair value much higher at about US$603.47, and anchors that view in long runway assumptions for Rezdiffra and Madrigal's broader MASH focus. The analysts have a consensus
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed [Yahoo! Finance]Yahoo! Finance
- Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 InhibitorGlobeNewswire
MDGL
Earnings
- 11/4/25 - Miss
MDGL
Sec Filings
- 12/12/25 - Form SCHEDULE
- 12/12/25 - Form SCHEDULE
- MDGL's page on the SEC website